Overview

Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer

Status:
Recruiting

Trial end date:
2023-09-30

Target enrollment:

Participant gender:

Summary

Aim of this phase III trial is to investigate the efficacy and safety of dronabinol (orally administered tetrahydrocannabinol (THC)) as adjuvant therapy to first-line standard chemotherapy in patients with metastatic pancreatic cancer for improvement of chemotherapy- and tumor-related symptoms applicated by individual titration up to the maximum tolerated dose.

Phase:

Phase 3

Details

Lead Sponsor:

Arbeitsgemeinschaft medikamentoese Tumortherapie

Collaborators:

Bionorica SE
Medical University of Graz
Unidata Geodesign

Treatments:

Dronabinol